Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

We recently published a list of Jim Cramer Discusses These 11 Stocks & Says Trump’s ‘Soft’ On Tariffs Amidst $4 Trillion ...

Johnson & Johnson MedTech has announced U.S. 510(k) regulatory clearance for MONARCH QUEST, the latest advancement in MONARCH ...

While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due ...

Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

Using Nvidia and GE Healthcare technology, the robotic surgery system is intended to help surgeons diagnose lung cancer ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Says Mag 7 Stocks Are A Thing Of The Past. In this ...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potent ...

We recently published a list of Jim Cramer Discusses These 12 Stocks & Says Mag 7 Stocks Are A Thing Of The Past.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

J&J's Neutrogena Skin360 service faces class action lawsuit over biometric privacy violations, with a judge ruling against ...